Louis J Picker

7514232, Apr 7, 2009

Feb 21, 1997

08/803702

Vernon C. Maino - Los Altos CA, US
Maria Suni - Los Gatos CA, US
Louis J. Picker - Plano TX, US

Becton, Dickinson and Company - Franklin Lakes NJ

G01N 33/00

435 724

This invention comprises a novel approach to the assessment of antigen-specific T cells that quantitates and characterizes these cells with unprecedented clarity, and importantly, because it is performed in whole blood, is amenable to routine use in the clinical immunology laboratory. The methodology offers an improved flow cytometric intracellular cytokine assay in whole blood that can simultaneously measure multiple T cell subsets expressing multiple cytokines from a single whole blood culture. Evaluation of whole blood antigen specific cytokine responses has the important advantage of assessing T cell activation in the presence of ALL types of MHC autologous antigen presenting cells present in the native sample. It also has the advantage of enabling a culture system (whole blood) which can reflect effects of systemic environments (i. e. drug augmentation or suppression) on T cell responses to specific stimuli including antigen, by either culturing in the presence of such drug or analyzing the blood of a human or animal receiving such drug.

20080199493, Aug 21, 2008

May 25, 2005

11/597457

Louis J. Picker - Portland OR, US
Michael Jarvis - Portland OR, US
Jay A. Nelson - Tualatin OR, US

A61K 39/21
C12N 15/63
A61P 31/18

4242081, 4353201

Particular aspects provide for use of the β-herpesvirus Cytomegalovirus (CMV: e.g., RhCMV and HCMV) as a uniquely evolved “vector” for safely initiating and indefinitely maintaining high level cellular and humoral immune responses (against, e.g., HIV, SIV, TB, etc.). Particular aspects provide a method for treatment or prevention of, e.g., HIV, SIV or TB, comprising infection of a subject in need thereof with at least one recombinant CMV-based vector (e.g., HCMV or RhCMV) comprising an expressible HIV/SIV/TB antigen or a variant or fusion protein thereof. In particular embodiments of the method, infection is of an immunocompetent, HCMV or RhCMV seropositive subject. Additional aspects provide for RhCMV- and HCMV-based vaccine vectors, and versions thereof with suicide or safety means. Further aspects provide pharmaceutical compositions comprising the inventive CMV-based vaccine vectors.

56121857, Mar 18, 1997

Sep 15, 1994

8/306525

Jonathan W. Uhr - Dallas TX
Ellen S. Vitetta - Dallas TX
Louis J. Picker - Dallas TX
Richard H. Scheuermann - Carrollton TX

Board of Regents, The University of Texas System - Austin TX

G01N 33574

435 723

Disclosed are methods for the identification and characterization of tumor cell types present within malignant populations, and novel methods of cancer treatment. Tumor cells in cell cycle arrest have been identified, purified and characterized according to their size, altered morphology, surface phenotype and expression of oncogenes. Tumor cell cycle arrest can be induced in mice lacking an immune system solely upon administration of anti-idiotype antibodies. Methods of manipulating specific signals from the cell surface to alter the malignant phenotype of transformed cells are disclosed, as are methods for either eliminating or specifically maintaining tumor cells in cell cycle arrest.

20220307054, Sep 29, 2022

Aug 19, 2020

17/636506

- Portland OR, US
Scott G. HANSEN - Portland OR, US
Daniel MALOULI - Hillsboro OR, US
Louis J. PICKER - Portland OR, US

C12N 15/86
C12N 5/0783
C07K 14/005
C07K 16/28
A61P 31/18
A61P 37/02

The disclosure relates to methods of modulating T cell responses by UL18 of human cytomegalovirus. The disclosure also relates to methods of generating MHC-Ia, MHC-II, and/or MHC-E restricted CD8+ T cells.

20220257740, Aug 18, 2022

Jun 5, 2020

17/616941

- Portland OR, US
Scott G. HANSEN - Portland OR, US
Louis J. PICKER - Portland OR, US

A61K 39/00
A61K 9/00
A61P 35/00

The present disclosure relates to antigens and methods of generating an immune response for the treatment of cancer. The disclosure also relates to methods of generating MHC-Ia, MHC-II, and/or MHC-E restricted CD8+ T cells for the treatment or prevention of cancer.

20220257748, Aug 18, 2022

Jun 5, 2020

17/616939

- Portland OR, US
Louis J. PICKER - Portland OR, US
Benjamin J. BURWITZ - Portland OR, US
Scott G. HANSEN - Portland OR, US
Jonah B. SACHA - Beaverton OR, US

A61K 39/12
A61P 31/12
A61K 39/00
A61K 47/30

The present disclosure relates to methods to generate an immune response for the treatment or prevention of hepatitis B virus infection. This disclosure also relates to methods to generate MHC-E and/or MHC-II restricted CD8 T cells for the treatment or prevention of hepatitis B virus infection.

20210403951, Dec 30, 2021

Jul 1, 2021

17/365509

- New York NY, US
- Portland OR, US
Aurelio M. Bonavia - New York NY, US
Dominick J. Laddy - New York NY, US
Louis Picker - Beaverton OR, US
Scott Hansen - Beaverton OR, US
Guangwu Xu - Beaverton OR, US

C12N 15/86
A61K 39/04
C07K 14/35

The present disclosure provides cytomegalovirus vectors encoding fusion proteins comprising (Mtb) antigens, nucleic acid molecules encoding the same, cytomegalovirus vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.

20200392534, Dec 17, 2020

Jan 9, 2020

16/738178

- Portland OR, US
Louis PICKER - Portland OR, US
Scott HANSEN - Portland OR, US
Jonah SACHA - Beaverton OR, US
Daniel MALOULI - Hillsboro OR, US

C12N 15/86
C12N 9/02
C12Q 1/68
C12N 15/00
A61K 39/12
A61K 35/17
A61K 39/21
A61K 39/245
C12N 7/00

Methods of inducing a CD8+ T cell response to a heterologons antigen in which at least 10% of the CD8+ T cells are MHC-E restricted are disclosed. The method involves immunizing with a CMV vector that does not express UL128 and UL130 proteins. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, a UL40 protein, and a US28 protein but that do not express an active UL128 and UL130 protein. Also, disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, but that do not express an active UL40 protein, UL128 protein, UL130 protein, and optionally a US28 protein. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, but that do not express an active US28 protein, UL128 protein, UL130 protein, and optionally a UL40 protein.